| Characteristic |
COVID-19 Severity
|
COVID-19 Mortality
|
| Overall, N = 102 |
Non-Critical, N = 65 |
Critical, N = 37 |
p-value |
Non-Survivor, N = 38 |
Survivor, N = 64 |
p-value |
| Sex |
|
|
|
0.9 |
|
|
>0.9 |
| F |
37 (36%) |
24 (37%) |
13 (35%) |
|
14 (37%) |
23 (36%) |
|
| M |
65 (64%) |
41 (63%) |
24 (65%) |
|
24 (63%) |
41 (64%) |
|
| Age |
57 (46, 64) |
54 (42, 62) |
61 (52, 68) |
0.007 |
63 (52, 71) |
53 (41, 62) |
<0.001 |
| OUTC |
|
|
|
<0.001 |
|
|
|
| Non-Survivor |
38 (37%) |
9 (14%) |
29 (78%) |
|
|
|
|
| Survivor |
64 (63%) |
56 (86%) |
8 (22%) |
|
|
|
|
| Diabetes |
|
|
|
0.2 |
|
|
0.3 |
| NO |
66 (65%) |
45 (69%) |
21 (57%) |
|
22 (58%) |
44 (69%) |
|
| SI |
36 (35%) |
20 (31%) |
16 (43%) |
|
16 (42%) |
20 (31%) |
|
| Hypertension |
|
|
|
0.006 |
|
|
<0.001 |
| NO |
43 (42%) |
34 (52%) |
9 (24%) |
|
8 (21%) |
35 (55%) |
|
| SI |
59 (58%) |
31 (48%) |
28 (76%) |
|
30 (79%) |
29 (45%) |
|
| Obesity |
|
|
|
0.5 |
|
|
0.6 |
| NO |
86 (84%) |
56 (86%) |
30 (81%) |
|
31 (82%) |
55 (86%) |
|
| SI |
16 (16%) |
9 (14%) |
7 (19%) |
|
7 (18%) |
9 (14%) |
|
| Chol |
122 (98, 157) |
124 (102, 160) |
121 (97, 154) |
0.5 |
128 (95, 161) |
121 (102, 144) |
>0.9 |
| Tryg |
144 (103, 202) |
138 (103, 202) |
146 (106, 200) |
0.7 |
161 (117, 214) |
136 (97, 178) |
0.032 |
| Unknown |
4 |
3 |
1 |
|
2 |
2 |
|
| LDLc |
67 (41, 89) |
69 (48, 92) |
52 (34, 86) |
0.064 |
60 (36, 94) |
68 (46, 87) |
0.3 |
| Unknown |
8 |
6 |
2 |
|
2 |
6 |
|
| HDLc |
30 (23, 38) |
30 (24, 36) |
26 (20, 42) |
0.7 |
27 (20, 39) |
30 (25, 38) |
0.5 |
| Unknown |
9 |
6 |
3 |
|
3 |
6 |
|
| CLIN |
|
|
|
|
|
|
<0.001 |
| Non-Critical |
|
|
|
|
9 (24%) |
56 (88%) |
|
| Critical |
|
|
|
|
29 (76%) |
8 (12%) |
|